Image credit: RefloDx
RefloDx announced the completion of a $2M seed round on October 19, 2026. The company is a Utah medical device maker focused on noninvasive, at-home testing. The round was filled by Crocker Ventures, Wild Tree Ventures, Convoi Ventures, Nucleus Fund, Park City Angels, TransAtlantic Angels, and several individual investors. The company did not name a lead investor.
The money will go toward SondeFlux, a wearable ultrasound device designed to detect stomach contents that reflux into the upper esophagus. Proceeds will cover finishing the device and its algorithm, plus a multi-center clinical development and blinded validation study.
RefloDx is chaired and led by Gregory Critchfield, M.D., M.S. The company says the problem is large. It estimates that 15 to 25 million people in the U.S. see a physician each year for persistent throat and voice symptoms such as chronic cough, hoarseness, throat clearing, difficulty swallowing, or a lump-in-the-throat sensation. Laryngopharyngeal reflux (LPR) is a principal cause, but the company notes that most patients with these symptoms have conditions unrelated to it.
Clinical consensus now recommends objective evidence of reflux before starting long-term drug therapy. The current best test uses catheters passed through the nose and down the throat. It is poorly tolerated and, according to the company, available to fewer than 5% of patients. The majority are therefore treated empirically with medication, which can delay the right diagnosis and add cost. RefloDx estimates the 2026 U.S. cost of working up and treating LPR at $70 billion.
Critchfield said the round lets the company complete development and validate a comfortable, noninvasive way to give doctors and patients answers. In his view, patients with reflux could be treated promptly, while those without it avoid unnecessary medications.
RefloDx’s clinical and scientific collaborators include laryngologists, gastroenterologists, and speech-language pathologists at the University of Utah, Mass General Brigham/Brigham and Women’s Hospital, and the Medical College of Wisconsin. The company plans to accelerate the development phase of the study in the fourth quarter of 2026, with blinded validation data expected in 2027. If validation succeeds, it is intended to support a future FDA marketing submission, pursuit of procedure codes for reimbursement, and, after FDA authorization, commercial launch.
SondeFlux is an investigational device. It has not been cleared by the FDA and is not commercially available. The market size and cost figures above come from the company’s press release.
